Related references
Note: Only part of the references are listed.Incidence, predictors, and prognostic impact of recurrent acute myocardial infarction in China
Jiali Song et al.
HEART (2021)
Gastrointestinal peptides and small-bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn's disease
Asseel Khalaf et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2020)
Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials
Cyrus DeSouza et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Mechanisms controlling hormone secretion in human gut and its relevance to metabolism
Alyce M. Martin et al.
JOURNAL OF ENDOCRINOLOGY (2020)
The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions
Marius Troseid et al.
EBIOMEDICINE (2020)
Targeting Interleukin-1 and Interleukin-6 The Time Has Come to Aggressively Address Residual Inflammatory Risk
Paul M. Ridker
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio et al.
MOLECULAR METABOLISM (2020)
The Association Between Femoral Artery Intima-Media Thickness and Serum Glucagon-Like Peptide-1 Levels Among Newly Diagnosed Patients with Type 2 Diabetes Mellitus
Tuan Dinh Le et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2020)
Glucagon-like peptide-1 receptor action in the vasculature
Malak Almutairi et al.
PEPTIDES (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Strategies to Overcome Residual Risk During Statins Era
Kyoung Im Cho et al.
CIRCULATION JOURNAL (2019)
ST-Segment-Elevation Myocardial Infarction (STEMI) Patients Without Standard Modifiable Cardiovascular Risk Factors-How Common Are They, and What Are Their Outcomes?
Stephen T. Vernon et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?
Daniela Stols-Goncalves et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2019)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Beyond conventional secondary prevention in coronary artery disease-what to choose in the era of CANTOS, COMPASS, FOURIER, ODYSSEY and PEGASUS-TIMI 54? A review on contemporary literature
Daniel Kalbacher et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats
Soo Lim et al.
CARDIOVASCULAR RESEARCH (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors
Stephen T. Vernon et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)
Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention
Francois Schiele et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)
The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis
Hideki Kushima et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Plasma Glucagon-Like Peptide-1 and Tissue Characteristics of Coronary Plaque in Non-Diabetic Acute Coronary Syndrome Patients
Takayuki Mitsuhashi et al.
CIRCULATION JOURNAL (2016)
SYNTAX score-0 patients: risk stratification in nonobstructive coronary artery disease
Christoph Sinning et al.
CLINICAL RESEARCH IN CARDIOLOGY (2016)
Does a Reduction in the Glomerular Filtration Rate Increase the Overall Severity of Coronary Artery Stenosis?
Junichi Nishida et al.
INTERNAL MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Alexandra M. Bodnaruc et al.
NUTRITION & METABOLISM (2016)
Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals
Tsutomu Hirano et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
PHYSIOLOGY OF PROGLUCAGON PEPTIDES: ROLE OF GLUCAGON AND GLP-1 IN HEALTH AND DISEASE
Darleen A. Sandoval et al.
PHYSIOLOGICAL REVIEWS (2015)
Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease
Thomas Idorn et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease
Christine Bernsmeier et al.
PLOS ONE (2014)
Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies
S. Calanna et al.
DIABETOLOGIA (2013)
Glucagon-Like Peptide-1 Secretory Function as an Independent Determinant of Blood Pressure: Analysis in the Tanno-Sobetsu Study
Mayumi Yoshihara et al.
PLOS ONE (2013)
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Racial disparity in glucagon-like peptide 1 and inflammation markers among severely obese adolescents
Pedro A. Velasquez-Mieyer et al.
DIABETES CARE (2008)
Share Paper
